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Lactococcus lactis is a commonly used starter strain that can be converted from a vitamin B2 consumer into a vitamin B2 ‘factory’ by over-expressing its
riboflavin biosynthesis genes. The present study was conducted to assess in a rat bioassay the response of riboflavin produced by GM or native lactic acid
bacteria (LAB). The riboflavin-producing strains were able to eliminate most physiological manifestations of ariboflavinosis such as stunted growth, elevated
erythrocyte glutathione reductase activation coefficient values and hepatomegalia that were observed using a riboflavin depletion–repletion model. Ribo-
flavin status and growth rates were greatly improved when the depleted rats were fed with cultures of L. lactis that overproduced this vitamin whereas the
native strain did not show the same effect. The present study is the first animal trial with food containing living bacteria that were engineered to overproduce
riboflavin. These results pave the way for analysing the effect of similar riboflavin-overproducing LAB in human trials.
Riboflavin: Lactic acid bacteria: Ariboflavinosis: Genetically modified micro-organisms
Riboflavin (vitamin B2) is a water-soluble vitamin belonging to
the B-complex group that is important for optimal body growth
and erythrocyte production and helps in releasing energy from
carbohydrates. In the body, riboflavin is primarily found as an
integral component of the coenzymes FAD and FMN. These
flavin-containing coenzymes participate in redox reactions in
numerous metabolic pathways such as the metabolism of carbo-
hydrates, fats and proteins. They are also involved in the meta-
bolism of folate, vitamin B12, vitamin B6, and other vitamins,
which explains why plasma riboflavin is a determinant of
plasma homocysteine, which is associated with CVD, pregnancy
complications, and cognitive impairment (Hustad et al. 2000,
2002).
Although riboflavin is found in a wide variety of foods (dairy
products, lean meats, poultry, fish, grains, broccoli, turnip
greens, asparagus, spinach and enriched food products), vitamin
B2 deficiency is common in many parts of the world, particularly
in developing countries (Boisvert et al. 1993). Several studies
have indicated that vitamin B2 deficiency may be widespread
in industrialised countries as well, both in the elderly (Bailey
et al. 1997; Madigan et al. 1998) and in young adults (Benton
et al. 1997).
Vitamin B2 status in human subjects has usually been assessed
by measuring the erythrocyte glutathione reductase activation
coefficient (EGRAC), which is the ratio between enzyme activity
determined with and without the addition of the cofactor FAD
(Glatzle et al. 1970). Glutathione reductase loses FAD at an
early stage in vitamin B2 deficiency, making the EGRAC a
useful method for the diagnosis of vitamin B2 deficiency
(Bates, 1993).
Riboflavin-deficient rat models have been utilised for a number
of years to study the biological effects of riboflavin. Using these
models, it has been shown that riboflavin: (i) is important in the
early postnatal development of the brain (Ogunleye & Odutuga,
1989) and gastrointestinal tract (Williams et al. 1995, 1996;
Yates et al. 2001, 2003); (ii) is able to modulate carcinogen-
induced DNA damage (Pangrekar et al. 1993; Webster et al.
1996); (iii) plays a role in Fe absorption and utilisation
(Powers, 1987; Powers et al. 1988, 1991, 1993; Butler &
Topham, 1993); (iv) can modulate inflammatory responses
(Lakshmi et al. 1991). These models also allow the extrapolation
of data obtained in an animal model to human clinical data
(Greene et al. 1990).
Previously, we described the genetic analysis of the riboflavin
biosynthetic (rib) operon in the lactic acid bacterium Lactococcus
lactis ssp. cremoris strain NZ9000 (Burgess et al. 2004). This
strain can be converted from a vitamin B2 consumer into a vita-
min B2 ‘factory’ by over-expressing its riboflavin biosynthesis
genes. Substantial riboflavin overproduction is seen in the
growth medium when all four biosynthetic genes (ribG, ribH,
ribB and ribA) are over-expressed simultaneously (in L. lactis
NZ9000 containing pNZGBAH). Also, spontaneous mutants
(i.e. L. lactis strain CB010) capable of producing riboflavin in
the growth medium, although at a lower level than the engineered
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strain, were identified. Such spontaneously riboflavin-overprodu-
cing strains have a considerable advantage over the genetically
engineered strain as they can be promptly implemented in indus-
trial fermentation.
The main objective of the present study was to evaluate the
bioavailability of riboflavin from spontaneous and engineered
riboflavin-overproducing L. lactis strains using a depletion–
repletion rat bioassay. These strains could be used in the develop-
ment of novel fermented foods containing increased levels of
riboflavin, produced in situ, which eliminates the need for vitamin
fortification.
Materials and methods
Bacterial strains, media and culture conditions
L. lactis strains NZ9000 (L. lactis B2 2 ) and CB010 (L. lactis
B2 þ ) were grown (12 h at 30 8C) in M17 medium (Biokar Diag-
nostics, Beauvais, France) supplemented with 0·5 % glucose
(M17-Glu). L. lactis NZ9000 harbouring plasmid pNZGBAH
(L. lactis B2þþ) (Burgess et al. 2004) were grown at 30 8C in
M17-Glu supplemented with chloramphenicol (5mg/ml). Nisin
was added (1 ng/ml) after 4 h growth when required.
Quantitative analysis of riboflavin in culture medium
Extracellular riboflavin concentrations of L. lactis cultures were
measured by reverse-phase HPLC using a modification of a pre-
viously described technique (Capo-Chichi et al. 2000). Briefly,
proteins from a cell-free supernatant fraction were precipitated
from a 1 ml sample by adding 10 % TCA. HPLC analysis (Isco
model 2360; Teledyne Isco Inc., Lincoln, NE, USA) of the result-
ing liquid was performed using a C18 reverse-phase column
(4 £ 150 mm; Varian, Inc., Palo Alto, CA, USA) with a linear
gradient of acetonitrile from 3·6 % to 30 % at pH 3·2 (HPLC-
grade water containing 0·1 % acetic acid). Fluorescent detection
was used and the excitation and emission wavelengths were 445
and 530 nm, respectively. Commercially obtained riboflavin,
FMN and FAD were used as references and to obtain a standard
curve (Sigma, Buenos Aires, Argentina).
Experimental design
The overall experimental protocol is summarised in Fig. 1. Ninety
weanling specific pathogen-free conventional Wistar rats (weigh-
ing 60^3 g) were obtained from the inbred colony maintained
(12 h light cycle; 22^28C) in the Nutrition Department of the
Universidad Nacional de Tucuma´n (Argentina). Rats were indivi-
dually housed in wire-based cages (to prevent coprophagy) and
were allowed free access to a riboflavin-deficient diet (ICN Bio-
medicals Inc., Irvine, CA, USA) and water throughout the study.
The rats were weight matched into three main groups of ani-
mals. The first group was a depleted group where animals were
fed the riboflavin-deficient diet during 42 d. The second group
was a non-depleted group where animals received the ribofla-
vin-deficient diet supplemented with commercial riboflavin
(15 mg B2/kg; Sigma, Buenos Aires, Argentina) during 42 d.
The third group was a depleted–replete group where rats were
fed the riboflavin-deficient diet for 21 d (depletion period) fol-
lowed by a 21 d repletion period where animals were fed the
same diet supplemented with (i) different levels of commercial
riboflavin, or (ii) wild-type or engineered riboflavin-producing
lactic acid bacteria (LAB; L. lactis B2 þ and L. lactis B2þþ ,
respectively) or (iii) the control strain (L. lactis B2 2 ), which
were grown in M17-Glu. Commercial riboflavin was added at
concentrations equivalent to: (i) the residual riboflavin found in
B2-free diets used in previous deficiency studies (0·5 mg B2/kg
diet; Powers et al. 1991, 1993; Yates et al. 2001, 2003); (ii) the
daily riboflavin requirement of laboratory rats (3·0 mg B2/kg
diet; Institute for Laboratory Animal Research, 1995). In the
second depleted–replete group, rats were fed 20 ml LAB-contain-
ing M17-Glu broth twice daily during the repletion period in
replacement of their drinking water, which contained 0·0
(SD 0·1), 0·5 (SD 0·2) or 15·0 (SD 5) mg/l for L. lactis B2 2 ,
B2 þ and B2þþ , respectively (determined by HPLC). Animal
live weight and food intake (given ad libitum) were determined
on a bi-daily basis. Growth rates were calculated during the
repletion period (21 d) using the mean average bi-daily increase
and were expressed as changes in live animal weight (g) per d.
Blood and organ collection
Throughout the trial, rats from each group were placed into a home-
made sampling chamber, and whole blood was collected from the
tail and transferred into a tube containing anticoagulant for
EGRAC evaluation (see p. 262). At the end of the trial, animals
were anaesthetised with an intraperitoneal injection of ketamin
(10 %)–xylacin (2 %) (3·0 ml/kg animal weight; 40:60, v/v; Alfa-
san, Woerden, The Netherlands) and bled by cardiac puncture.
Blood was transferred into tubes containing anticoagulant (heparin;
Rivero, Buenos Aires, Argentina) and centrifuged (2000 g for
15 min at 48C). Plasma was removed and stored at 2708C until
analysis. The sedimented cells were washed three times with cold
0·15 M-NaCl. Erythrocytes (0·5 ml) were haemolysed by adding dis-
tilled water (9·5 ml) and stored at 2708C for EGRAC determi-
nations. Freshly excised organs (liver, spleen and kidneys) were
rinsed with 0·15 M-NaCl, weighed and stored at 2708C.
Riboflavin status
Riboflavin status was assessed by measuring the EGRAC using a
modification of a previously described technique (Adelekan &
Thurnham, 1986). Briefly, haemolysed blood was allowed to
Fig. 1. Riboflavin depletion–repletion experimental protocol. The depleted
group were fed a riboflavin-deficient diet (RDD) during 42 d; the non-depleted
group received the RDD supplemented with commercial riboflavin during
42 d; the depleted–replete group were fed the RDD for 21 d (depletion period)
followed by a 21 d repletion period where animals were fed the same diet sup-
plemented with (i) different levels of commercial riboflavin, or (ii) wild-type or
engineered riboflavin-producing lactic acid bacteria (Lactococcus lactis B2 þ
and L. lactis B2þþ , respectively) or the control strain (L. lactis B2 2 ).
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thaw at room temperature under conditions of reduced light. Hae-
molysates (31·3ml) were added to 1 ml potassium phosphate
buffer (0·1 M; pH 7·4) containing 2·3 mM-ethylenediaminetetra-
acetic acid (dipotassium salt) and 0·89 mM-GSSG with or without
8mM-FAD. The mixture was pre-incubated for 30 min at 378C
followed by the addition of 80mM-NADPH to initiate the reac-
tion. The absorbance at 340 nm was measured every 10 min
during 1 h at 378C. Riboflavin status was calculated as the ratio
(activity coefficient) of the rate of change of absorbance per
time unit in the presence or absence of FAD. EGRAC were
measured in triplicate for each sample.
Statistics
Comparisons were performed using the software package Sigma-
Stat (SPSS Inc., Chicago, IL, USA). Comparisons of multiple
means were accomplished by one-way ANOVA followed by
Tukey’s post hoc test and P,0·05 was considered significant.
Unless otherwise indicated, all values are the means of three inde-
pendent trials and standard deviations (where n 30).
Results and discussion
In order to study the bioavailability of riboflavin from native and
engineered L. lactis strains, a depletion–repletion rat bioassay
was used. Conventional Wistar rats were fed a riboflavin-deficient
diet and their riboflavin status was followed using growth rate and
EGRAC as indicators. The bioavailability of the riboflavin pro-
duced by the bacterial strains was compared with that of pure
riboflavin given to rats at levels previously considered negligible
(0·5 mg/B2 kg diet) or at the daily recommended intake for such
animals (3·0 mg B2/kg diet; for details, see p. 262).
Animal growth during the depletion–repletion periods
It is well documented that rats, which are deprived of riboflavin,
exhibit an impairment of growth (Glatzle et al. 1968). Animal
growth was followed throughout the trials. At the end of the
depletion and repletion periods, a significant decrease was
observed in the growth rate and final weight of the riboflavin-
depleted rats as compared with the non-depleted group (Table 1).
The animals supplemented with L. lactis B2 2 showed signifi-
cantly lower growth rates (2·78 (SD 0·17) g/d) as compared with
those fed L. lactis B2 þ or 0·5 mg B2/kg (3·30 (SD 0·20) and
3·19 (SD 0·16) g/d respectively), suggesting that the riboflavin
produced by the latter strains can exert a biological function.
The L. lactis B2 2 rats showed higher growth rates than the
depleted animals, which only received the riboflavin-deficient
diet (0·68 (SD 0·04) g/d). This last difference could be due to
other residual nutrients found in the M17 broth after bacterial
growth besides riboflavin since this vitamin was not detected
after growth of L. lactis B2 2 (HPLC determination). Interest-
ingly, the animals that received L. lactis B2 þ showed
statistically similar growth rates as the group that received
0·5 mg B2/kg, suggesting that the riboflavin produced by this bac-
terial strain, given here at the same concentration as the commer-
cially available pure riboflavin, possesses similar bioavailability.
The animals that received L. lactis B2þþ showed a significantly
higher growth rate (4·41 (SD 0·26) g/d) and final weight (224·0 (SD
13·4) g) than all the other depleted–replete groups (Table 1), an
expected result since the riboflavin concentration of this culture
(15·0 (SD 5) mg/l) was the highest used in the depleted–replete
animals. The food consumption during the depletion and repletion
periods did not differ significantly between the different exper-
imental groups (data not shown).
Riboflavin status (erythrocyte glutathione reductase activation
coefficient)
Activation assays such as the EGRAC are functional tests that
show a decline in a specific enzyme activity as a result of ribofla-
vin deficiency and a disproportionate increase in activity after the
in vitro addition of this vitamin (Adelekan & Thurnham, 1986).
The rate of change of the assay is proportional to the amount of
enzyme present. EGRAC values of 1·30 to 1·40 or higher are
indicative of biochemical riboflavin deficiency. Riboflavin
status, expressed in terms of the activation coefficient for the
FAD-dependent enzyme erythrocyte glutathione reductase (EC
1.6.4.2), was determined throughout the study.
In order to show that EGRAC values correlate with the ribofla-
vin status of rats, a validation test was performed where the
EGRAC was followed at a weekly basis in animals fed with the
Table 1. Growth rate and live weight of animals fed a riboflavin-deficient diet during 21 d (depletion period), after
which they received the same diet supplemented with commercial riboflavin or Lactococcus lactis strains (NZ9000
(B2 2 ), CB010 (B2 þ ), or NZ9000 (pNZGBAH) (B2þþ)) during 21 d (repletion period)
(Mean values and standard deviations)
Depletion period Repletion period
Growth rate (g/d) Final weight (g) Growth rate (g/d) Final weight (g)
Group* Mean SD Mean SD Mean SD Mean SD
Non-depleted 5·81a 0·35 138·0a 8·3 5·34a 0·32 299·2a 18·0
Depleted 4·08b 0·24 102·2b 6·1 0·68b 0·04 141·1b 8·5
L. lactis (B2 2 ) 2·78
f 0·17 188·9c 11·3
B2 (0·5mg) 3·19
c 0·16 190·0c 9·5
B2 (3·0mg) 3·61
d 0·22 204·2c,d 12·5
L. lactis (B2þþ ) 4·41e 0·26 224·0e 13·4
L. lactis (B2 þ ) 3·30c 0·20 200·0c,d 12·0
a,b,c,d,e,fMean values within a column with unlike superscript letters are significantly different (P,0·05).
*Sixty rats in the depleted group during the depletion period and ten rats in all groups during the repletion period and for the non-depleted
group during the depletion period.
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riboflavin-deficient diet (depleted group). A significant increase in
EGRAC values can be observed in the depleted group as
compared with the non-depleted groups (Fig. 2). After only 7 d,
a significant increase in the EGRAC is seen in the depleted
group (1·62 (SD 0·09)) and this value continues to increase in
function of time (2·02 (SD 0·07) and 2·41 (SD 0·06) after 21 and
42 d, respectively). In the non-depleted group, EGRAC values
did not vary significantly (1·18–1·29) showing that their ribofla-
vin status remained normal throughout the study.
In order to determine if native and engineered LAB could
improve the riboflavin status of deficient rats, cultures grown in
M17-Glu were used to supplement the riboflavin-deficient diet
for 21 d (repletion period) of previously depleted animals.
HPLC analysis showed significant levels of riboflavin in the
M17-Glu medium following growth of L. lactis B2 þ or
B2þþ(0·5 (SD 0·2) and 15 (SD 5) mg/l respectively). This vitamin
was below the detection level in the medium after growth of the
non-producing strain (L. lactis B2 2 ).
As was the case in the validation test, the depleted rats showed
increased EGRAC values (2·41 (SD 0·06)) compared with the non-
depleted animals (1·18 (SD 0·04)) after the repletion period (Fig. 3).
The rats whose diet was supplemented with the non-producing
strain (L. lactis B2 2 ) showed statistically similar EGRAC
values as those found in the depleted animals (2·35 (SD 0·06)).
This result confirms that the increase in growth observed in the ani-
mals supplemented with the non-producing strains is not caused by
riboflavin but by other residual nutrients found in the cultures
broth. The rats whose diet was supplemented with either of the
two riboflavin producing strains (L. lactis B2 þ and B2þþ)
exhibited significantly lower EGRAC values (1·65 (SD 0·09) and
1·31 (SD 0·05), respectively) as compared with rats of the depleted
group (2·41 (SD 0·06)) or rats whose diet was supplemented with
the non-producing strain (L. lactis B2 2 ) (2·10 (SD 0·06))
(Fig. 3). Interestingly, the animals that received L. lactis B2 þ
showed statistically similar EGRAC values as the group that
received 0·5 mg B2/kg, suggesting that the riboflavin produced
by this bacterial strain, given here at the same concentration as
the commercially available pure riboflavin, possesses similar bio-
availability, confirming the results seen in growth (Table 1).
The animals that received L. lactis B2þþ showed the lowest
EGRAC values and, as was the case with the growth rates, this
result was not surprising since the riboflavin concentration of
this culture was the highest used in the depleted–replete animals.
Surprisingly, no statistically significant differences in EGRAC
values were observed between the animals that received 0·5 mg
B2/kg and those receiving 3·0 mg B2/kg (however, absolute
values were lower in the 3·0 mg B2/kg group compared with the
0·5 mg B2/kg group); a longer repletion period in future studies
could improve the sensibility of the experiment.
Organ weight comparison
Another physiological effect of ariboflavinosis is hepatomegaly,
which is the enlargement of the liver beyond its normal size.
This problem is normally found in rats deficient in riboflavin
(Glatzle et al. 1968).
An increase in the weight of the liver in relation to body weight
was observed in the depletion groups where riboflavin deficiency
was observed (Fig. 4).
The groups supplemented with L. lactis B2 2 showed a signifi-
cant increase in relative liver weight (5·4 (SD 0·5) g) as compared
with the non-depleted group (4·4 (SD 0·2) g) and were statistically
similar to the depletion groups (5·2 (SD 0·4) g) and the group that
received 0·5 mg B2/kg (5·3 (SD 0·5) g). The groups supplemented
with L. lactis B2 þ or L. lactis B2þþ showed no significant
differences in relative liver weight compared with the non-
depleted group or the group that received 3·0 mg B2/kg. These
results suggest that the riboflavin-producing strains are able to
decrease the relative liver weight increases observed in the
depleted animals. However, it is not possible to assess bioavail-
ability of the riboflavin produced by the bacterial strains with
these results since no significant differences were observed in
the animals fed with either the producing strain (B2 þ ) or the
overproducing strain (B2þþ ), which have very important
Fig. 2. Erythrocyte glutathione reductase activation coefficient (EGRAC)
values of rats fed a riboflavin-deficient diet (B) or the same diet sup-
plemented with commercial riboflavin (15mg/kg; A). Values are means, with
standard deviations represented by vertical bars (n 10). a,b,c,d Mean values
with unlike letters are significantly different (P,0·05).
Fig. 3. Erythrocyte glutathione reductase activation coefficient (EGRAC)
values of rats fed a riboflavin-deficient diet during 21 d followed by a 21d
repletion period where the diet was supplemented with different amounts of
riboflavin (0, 0·5 or 3·0mg/kg diet) or with cultures of Lactococcus lactis
(NZ9000 (B2 2 ), CB010 (B2 þ ), or NZ9000 (pNZGBAH) (B2þþ)). Values
are means, with standard deviations represented by vertical bars (n 10).
a,b,c,dMean values with unlike letters are significantly different (P,0·05).
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differences in bioavailable riboflavin as determined by HPLC,
growth rates and EGRAC values.
No changes in haematological values or morphology of blood
cells were observed in these trials (data not shown). This was
an expected result since it was previously shown that riboflavin
deficiency alone is not sufficient to change the haematological
status of rats (Adelekan & Thurnham, 1986). Also, there were
no differences in relative spleen and kidney weights in all experi-
mental groups (data not shown).
Conclusions
The objective of the present study was to evaluate the bioavail-
ability of riboflavin from spontaneous and engineered ribofla-
vin-overproducing L. lactis strains using a depletion–repletion
rat bioassay. The bioavailability of the riboflavin produced by
these strains is similar to that of pure riboflavin, taking into
account growth rates and EGRAC values as indicators of the bio-
logical function of this vitamin. The addition of riboflavin-produ-
cing strains was shown to clearly improve the growth (Table 1)
and riboflavin status of the depleted animals as shown by signifi-
cant decreases to EGRAC values in rats supplemented with the
engineered or native riboflavin-producing strains, where values
reach similar levels as those seen in the non-depleted group
(Fig. 3). Also, the riboflavin-producing strains were capable of
curing hepatomegaly resulting from ariboflavinosis (Fig. 4).
The safety of use of novel strains must be addressed when they
are to be proposed to be inserted into the food chain. In the pre-
sent study no secondary effects were observed in animals fed the
GM strains and haematological values, morphology of blood
cells, and relative weight of organs of these animals were all simi-
lar to those obtained in the non-depleted groups. Only positive
results were observed with the use of these strains, such as
improved animal growth, EGRAC values and relative organ
weight. The GM riboflavin-producing strain (L. lactis B2þþ)
has been the object of a complete biosafety assessment in our
laboratory and has been shown to be innocuous to the host
(LeBlanc et al. 2005). Current legislation in most countries
does not allow the addition of live GM strains in food products
for human consumption, strongly limiting the use of the overpro-
ducing strain used in the present study. However, the use of spon-
taneous mutants, such as the riboflavin-producing strain, is
generally accepted, greatly improving the possibilities that this
strain could be included in novel products in a relatively short
timeframe.
The present study has provided the first animal trial with food
containing living bacteria that were selected or engineered to pro-
duce extracellular riboflavin in the fermented product. These
results pave the way for analysing the effect of similar ribofla-
vin-overproducing LAB in human trials. The development of fer-
mented foods containing increased levels of riboflavin, produced
in situ, which eliminates the need for vitamin fortification is cur-
rently underway. Since fermentation with L. lactis is a common
practice in the dairy industry, the addition of the riboflavin-produ-
cing strain into products such as fermented milks, yoghurt, and
cheeses in order to increase riboflavin concentrations is feasible
and economically attractive since it would decrease the costs
involved in current practices of vitamin fortification. The con-
sumption of such products with increased levels of riboflavin on
a regular basis could help prevent deficiencies of this important
vitamin. Such products could decrease the costs incurred when
mandatory fortification programmes are elaborated, such as
those now in place in many industrialised countries.
The present study is one of many currently being addressed
by the European NutraCells consortium (www.nutracells.com).
The achievements of this multinational project should open the
door to many applications in the development of both new food
products with enhanced nutritional value and probiotic prep-
arations with well-demonstrated in vivo activity.
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